Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2024-03-05 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2024-03-05 English
Preliminary FY Results & 2024 Guidance
Earnings Release Classification · 1% confidence The document is a press release issued via the Regulatory News Service (RNS) by MaxCyte, Inc. It provides preliminary financial results for 2023 and initial revenue guidance for 2024. While it contains financial data, it is an initial announcement of results rather than a full quarterly or annual report. According to the filing definitions, an initial announcement of financial results is classified as an Earnings Release (ER). FY 2023
2024-03-05 English
Director's Dealing 2024
Director's Dealing
2024-03-04 English
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the total number of voting rights and issued share capital following the issuance of new common stock. This type of disclosure is a standard regulatory requirement for companies listed on the London Stock Exchange (LSE) to inform shareholders of the denominator for calculating interest notifications. While it involves share issuance, it is specifically categorized as a 'Total Voting Rights' announcement, which falls under the broader regulatory filing category for share capital changes and transparency requirements.
2024-03-01 English
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically a Non-Executive Director (John Johnston) exercising options and selling shares. The text explicitly includes the standard regulatory disclosure tables for PDMR dealings, which is the hallmark of a Director's Dealing filing. It is not a report publication announcement, but rather the primary disclosure itself.
2024-02-29 English
Director's Dealing 2024
Director's Dealing
2024-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.